MK-2866 (Ostarine)
A selective androgen receptor modulator tested in over 1,700 subjects that failed FDA approval for muscle wasting.
Medications & hormones
Research records
Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.
Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.
MK-2866 (Ostarine)
A selective androgen receptor modulator tested in over 1,700 subjects that failed FDA approval for muscle wasting.
Evidence category: Preclinical. This describes the source category, not approval or certainty.
Regulatory statement in source: Not FDA-approved.
MK-2866 (Ostarine, Enobosarm) is a nonsteroidal selective androgen receptor modulator studied in over 25 controlled clinical trials involving 1,700+ subjects—the largest SARM clinical dataset. However, it failed Phase III trials for lung cancer-associated muscle wasting in mid-2013. Despite extensive research, no SARM compound has received FDA approval.
Benefits reported in the imported source
- Selective AR activity in muscle and bone
- No aromatization to estrogen; no 5-alpha reduction
Risks and limits
- Classified as Investigational New Drug (IND)
- Suppression of endogenous testosterone
Source bottom line: Extensive clinical research (1,700+ subjects) failed to achieve FDA approval; remains investigational.
Uncertainty: Reference information only. Not medical advice.
Study protocols — reports, not instructions
No study protocol recorded in this snapshot. This does not establish that no study exists.
Community and practice descriptions
Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.
Unverified imported account — Ostarine (MK-2866): Results, Before and After Pictures, Dosages
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A bodybuilding resource documents ostarine protocols reporting 20 mg daily for 8 weeks as typical for men pursuing fat loss and muscle retention, with extended cycles to 12 weeks conducted only if health markers remain within acceptable ranges.
Ostarine (MK-2866): Results, Before and After Pictures, Dosages
Unverified imported account — Ostarine (MK-2866): Results, Before and After Pictures, Dosages
An imported authored paraphrase, not a quotation or a recommended protocol.
Review: unverified historical account. The imported wording is preserved for attribution; its full clinical, dosing, efficacy or consensus claims have not been independently established. Unvalidated source account; no validated human dosing population or animal-to-human equivalence is inferred.
Imported wording: A fitness guide describes female ostarine protocols of 10 mg daily for 4 to 8 weeks, with case studies documenting cycles using 12.5 mg initially then 25 mg for subsequent weeks.
Ostarine (MK-2866): Results, Before and After Pictures, Dosages
Pharmacokinetic context
Historical half-life estimate: 14–24 hours. Human clinical PK data (Dalton JT group trials; Jones et al. 2013 metabolite study, PMID 27105861) — most rigorously human-studied SARM on this list Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.
Source references
Snapshot provenance
Source ID: catalog:hormone:mk-2866. Commit: adc7684614f9439b41d91a3312b62e7982c7e20e. Review state: historical-not-reverified. Authored links are retained separately from the canonical evidence links in the public data. App templates/defaults and rejected drafts are archived, not deployed.
Related entries and components
None listed.